Suggestions
Sofie Pattijn
Chief Technology Officer and Founder at ImmunXperts, a Nexelis Group Company
Sofie Pattijn is the Chief Technology Officer (CTO) and co-founder of ImmunXperts, a contract research organization (CRO) specializing in immunogenicity assessments and immuno-oncology research. With over 20 years of experience in the field, she has played a pivotal role in the development and growth of ImmunXperts since its founding in 2014.
Professional Background
-
Founding ImmunXperts: Sofie co-founded ImmunXperts with the vision of providing personalized and flexible support for drug development processes, particularly in immuno-oncology and cellular therapies. The company aims to address gaps in the industry by offering tailored solutions to clients' specific needs.12
-
Experience: Before establishing ImmunXperts, Sofie worked with both large corporations and smaller companies, gaining extensive knowledge in immunology and drug development. Her diverse background has equipped her to understand the complexities of drug development and the importance of immunogenicity assessments.23
Role at ImmunXperts
As CTO, Sofie's responsibilities include:
- Technology Development: Leading efforts to explore new technologies and methodologies that enhance the company's service offerings.
- Customer Engagement: Directly interacting with clients to understand their challenges and provide effective solutions.
- Team Leadership: Supporting and training scientists within the organization to foster a collaborative work environment.12
Vision and Impact
Sofie emphasizes the importance of staying ahead in a rapidly evolving field like immuno-oncology. She believes that continuous learning and adaptation are crucial for meeting client demands and advancing therapeutic solutions. Her leadership has fostered a culture of innovation at ImmunXperts, making it a preferred partner for many organizations in drug development.13
In summary, Sofie Pattijn's extensive experience, combined with her commitment to personalized service, positions her as a significant figure in the field of immunology and drug development.